Testing the Addition of Chemotherapy Drug, Cisplatin, to Usual Radiation Therapy for Patients with Head and Neck Cancer

G
Greg Durm, MD

Primary Investigator

Recruiting
18 years - 100 years
All
Phase 2
7 participants needed
2 Locations

Brief description of study

The purpose of this study is to compare two treatment approaches that are currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone. A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.

Detailed description of study

Participants will be assigned to receive either radiation therapy, or radiation therapy along with cisplatin. Both groups will receive treatment for 6 weeks with the doctor following their condition for 10 years after treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Head and Neck Cancer
  • Age: 18 years - 100 years
  • Gender: All

Individuals at least 18 years of age with squamous cell carcinoma of the head/neck, that has been surgically removed.

Individuals with recurrent disease or multiple primaries will not be eligible.

Women who are pregnant or breastfeeding will not be eligible.

Updated on 01 Aug 2024. Study ID: 1908611001

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center